{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-027012","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.039233+00:00","generated_at":"2026-05-31T08:56:35.375152+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CervoMed reports Q2 2024 net loss $2.3M, cash $50.9M; DLB trial enrolled, topline Dec 2024","bullets":["Net loss $2.3M in Q2 2024 vs $1.4M in Q2 2023; operating loss $3.0M vs $1.2M.","Cash, equivalents and marketable securities $50.9M at June 30, 2024, up from $7.8M at Dec 31, 2023.","Completed enrollment in Phase 2b RewinD-LB trial (neflamapimod for early-stage DLB) in June 2024; topline data expected Dec 2024.","Private placement in April 2024 raised $50M upfront, with potential total proceeds up to $149.4M.","NIA grant revenue $5.6M for H1 2024 vs $3.1M for H1 2023; cash runway extended through 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-027012","json":"https://secwatch.observer/filing/0001437749-24-027012.json","markdown":"https://secwatch.observer/filing/0001437749-24-027012.md","text":"https://secwatch.observer/filing/0001437749-24-027012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924027012/0001437749-24-027012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774924027012/crvo20240815_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:56:35.375152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}